Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Naik, Haley B.; Alhusayen, Raed; Frew, John W.; Guilbault, Sandra; Hills, Nancy K.; Ingram, John R.; Kudlinski, Margaret V; Lowes, Michelle A.; Marzano, Angelo Valerio; Paul, Maia; Villumsen, Bente; Yannuzzi, Christine A.

doi:10.1016/j.jaad.2021.09.016

Cited by 12 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we report the most recent data from the Global Hidradenitis Suppurativa COVID-19 Registry, which further demonstrate that HS patients on biologics do not have higher odds of hospitalization or require respiratory support compared to those on nonbiologic therapies. Although previous studies of smaller HS cohorts have reported similar findings [ 1 , 2 ], the findings from this report, which includes 126 cases (105 self/caregiver-reported and 21 HCP-reported) that were reported after the introduction of COVID-19 vaccines, are notable given that anti-TNF therapy is associated with faster declines in COVID-19 vaccine-induced neutralizing antibodies in patients with chronic inflammatory diseases [ 3 ].…”

supporting

confidence: 53%

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 53%

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…39 To sum up, the role of telemedicine in patients affected by HS seems to be limited since several concerns remain such as patient emotional distress, patient comfort and privacy, difficulties to show intimate areas, inability for clinicians to palpate lesions. [40][41][42][43][44] Thus, new strategies and new studies are required.…”

Section: Dovepressmentioning

confidence: 99%

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Ruggiero¹,

Fabbrocini²,

Villani³

et al. 2022

CCID

View full text Add to dashboard Cite

Teledermatology represented one of the most important and useful tools during the COVID-19 pandemic era. Indeed, due to the severe restriction, and to reduce the spread of the infection, different measures were applied among different countries and hospitals to ensure a continuity of care for patients. In this scenario, teledermatology played a central role, especially in the management of patients suffering from chronic inflammatory skin diseases. The aim of this narrative review is to describe the role of teledermatology during the COVID-19 pandemic to analyze main strengths and limitations of this tool, as well as to provide future perspectives in clinical applications.

show abstract

“…Ongoing studies, such as the University of California San Francisco led Global Hidradenitis Suppurativa COVID-19 Registry, will provide further data to guide recommendations in this patient population. Initial findings demonstrate that biologic therapies have not been associated with increased COVID-19 severity [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

Rick

Shih

et al. 2022

Skin Appendage Disord

Self Cite

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven consensus recommendations regarding COVID-19 vaccinations in HS patients. Methods: A modified Delphi consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until consensus (≥70% agreement) was achieved. Results: Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round. Discussion/Conclusion: For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.

show abstract

Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Cited by 12 publications

References 5 publications

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

Contact Info

Product

Resources

About